10 RESULTS
COMMENT Plasma p-tau has the potential to revolutionize the diagnostic work-up of Alzheimer’s disease in the near future. Plasma p-tau181 and p-tau217 can with very high accuracy differentiate AD dementia from other neurodegenerative diseases, with similar ...
COMMENT I think this is a truly exciting development for AD diagnostics! We now need to develop appropriate use criteria to avoid misuse and misinterpretation of new blood tests for diagnosis of Alzheimer’s disease, similar to what has already been done for CSF ...
COMMENT Lim and colleagues use a language-learning test, with repeated learning sessions containing the same learning material, to investigate learning performance (instead of memory performance) in 80 older adults. Following a supervised first learning session, ...
COMMENT The paper describes changes in plasma concentrations of P-tau181 in familial Alzheimer’s disease. The authors found that similar to plasma NfL, the P-tau181 concentrations started to increase around 15 years prior to symptom onset. The unadjusted ...
COMMENT A crucial step in the validation of a PET tracer for tau pathology is the comparison of in vivo tracer retention and neuropathological verification of the pathology postmortem. Adam Fleisher and colleagues have now performed a relatively large end-of-life ...
COMMENT The study is very well-performed and corroborates earlier studies showing that adding plasma Aβ42/40 to an algorithm that includes age, sex, APOE genotype, and clinical diagnosis somewhat improves the ability of the model to predict amyloid positivity. ...
COMMENT I think the paper is very well performed and the results indicate that tau pathology is more closely related to cognitive decline than Aβ pathology. More importantly, the study indicates that it is the rate in increase in tau pathology (as measured with ...
COMMENT This consensus paper is a major step forward for the development of an accurate definition of Alzheimer’s disease. We are soon approaching a stage where at least one of the dementia disorders can be defined in vivo based on evidence of the presence of key ...
COMMENT Longitudinal biomarker studies are very important to better understand the molecular changes in AD. However, considering the protracted disease course of AD (spanning two to three decades), we probably need intra-individual measurements over at least ...
COMMENT I fully agree that further work is needed, such as evaluating whether the test adds to the diagnostic work-up of uncertain cases of parkinsonism, especially in a setting where the patients are examined by medical doctors who are not specialists in ...
